Molecularly Distinct Clathrin-Coated Pits Differentially Impact EGFR Fate and Signaling
Roberta Pascolutti,
Veronica Algisi,
Alexia Conte,
Andrea Raimondi,
Mithun Pasham,
Srigokul Upadhyayula,
Raphael Gaudin,
Tanja Maritzen,
Elisa Barbieri,
Giusi Caldieri,
Chiara Tordonato,
Stefano Confalonieri,
Stefano Freddi,
Maria Grazia Malabarba,
Elena Maspero,
Simona Polo,
Carlo Tacchetti,
Volker Haucke,
Tom Kirchhausen,
Pier Paolo Di Fiore,
Sara Sigismund
Affiliations
Roberta Pascolutti
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy
Veronica Algisi
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy
Alexia Conte
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Andrea Raimondi
Experimental Imaging Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
Mithun Pasham
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
Srigokul Upadhyayula
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA
Raphael Gaudin
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA; Institut de Recherche en Infectiologie de Montpellier, UMR 9004, CNRS/UM, 1919 route de Mende, 34293 Montpellier cedex 5, France
Tanja Maritzen
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
Elisa Barbieri
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Giusi Caldieri
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy
Chiara Tordonato
Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Stefano Confalonieri
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Stefano Freddi
Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Maria Grazia Malabarba
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy
Elena Maspero
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy
Simona Polo
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy
Carlo Tacchetti
Experimental Imaging Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy
Volker Haucke
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany
Tom Kirchhausen
Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
Pier Paolo Di Fiore
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy
Sara Sigismund
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy; Corresponding author
Summary: Adaptor protein 2 (AP2) is a major constituent of clathrin-coated pits (CCPs). Whether it is essential for all forms of clathrin-mediated endocytosis (CME) in mammalian cells is an open issue. Here, we demonstrate, by live TIRF microscopy, the existence of a subclass of relatively short-lived CCPs lacking AP2 under physiological, unperturbed conditions. This subclass is retained in AP2-knockout cells and is able to support the internalization of epidermal growth factor receptor (EGFR) but not of transferrin receptor (TfR). The AP2-independent internalization mechanism relies on the endocytic adaptors eps15, eps15L1, and epsin1. The absence of AP2 impairs the recycling of the EGFR to the cell surface, thereby augmenting its degradation. Accordingly, under conditions of AP2 ablation, we detected dampening of EGFR-dependent AKT signaling and cell migration, arguing that distinct classes of CCPs could provide specialized functions in regulating EGFR recycling and signaling. : EGFR signaling controls different cell physiological processes, including proliferation and migration. Pascolutti et al. describe an additional layer of regulation of EGFR signaling, relying on the sequestration of receptors into molecularly distinct clathrin-coated vesicles that regulate receptor fate toward recycling versus degradation, with impact on the final cellular output. Keywords: EGFR, endocytosis, clathrin-coated pits, AP2, eps15, epsin, endocytic adaptors, signaling, receptor degradation, recycling, transcription